West Pharmaceutical Services, Inc. - 2002 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2002. West Pharmaceutical Services, Inc. applies value-added technologies to bring new drug therapies and healthcare products to global markets. The Company operates through two reportable segments:
- Pharmaceutical Systems: Designs, manufactures, and sells stoppers, closures, and medical device components (elastomers, metals, plastics) and provides contract laboratory services.
- Drug Delivery Systems: Develops drug delivery systems for biopharmaceuticals and operates a clinical services organization conducting Phase I through Phase IV trials.
As of December 31, 2002, the Company employed 4,140 people. International sales accounted for approximately 46% of consolidated net sales.
Key Financial Metrics
Note: Specific consolidated revenue, net income, cash flow, and total debt figures for 2002 are incorporated by reference to the 2002 Annual Report to Shareholders and are not explicitly stated in the provided text.
- Order Backlog (Pharmaceutical Systems): Approximately $119 million at December 31, 2002 (up from $105 million in 2001).
- Order Backlog (Drug Delivery Systems): $1.3 million at December 31, 2002 (down from $2.0 million in 2001).
- Development Expenditures:
- Pharmaceutical Systems: $10.6 million (2002), $10.0 million (2001).
- Drug Delivery Systems: $10.9 million (2002), $7.8 million (2001).
- Debt Instruments: Includes $100,000 in senior notes (fixed rate), variable rate notes payable, and revolving credit facilities. A specific interest rate swap with a notional amount of 6,950 British Pound Sterling ($11,200) was active.
- Dividends: Quarterly dividends were $0.19 per share for the first three quarters of 2002 and $0.20 per share for the fourth quarter.
- Stock Price (2002): High of $32.50, Low of $16.25.
Material Changes and Recent Developments
- Tragic Incident (Subsequent Event): On January 29, 2003, an explosion and fire occurred at the Kinston, N.C. plant, resulting in six fatalities, injuries, and substantial damage to facilities and inventory. A class-action lawsuit was filed on February 24, 2003, seeking unspecified damages.
- Asset Sales:
- Sold consumer healthcare research unit in December 2002 for $2.0 million (no gain/loss recorded due to prior $0.6 million goodwill impairment).
- Sold contract manufacturing and packaging business in 2001 for $29.8 million, resulting in a $25.2 million loss on disposal.
- Leadership Change: Donald E. Morel, Jr., Ph.D., became Chairman, CEO, and President in early 2003, succeeding William G. Little.
- Customer Concentration: Becton Dickinson and Company ("BD") accounted for approximately 13% of 2002 consolidated net sales. The next ten largest customers accounted for 31% combined.
Outlook, Risks, and Contingencies
- Legal Contingency: The Company faces potential liability from the Kinston plant explosion lawsuit. While the Company typically obtains indemnification from trial sponsors for clinical services, this excludes negligence or misconduct.
- Environmental Remediation: The Company has reserved $0.9 million for remediation at three facilities (Phoenixville, PA; Wayne, NJ; St. Petersburg, FL). Completion is expected between 2003 and 2004.
- Market Risks:
- Foreign Currency: 46% of sales are international; results are exposed to exchange rate fluctuations. The Company generally does not hedge these exposures but attempts to pass costs to customers.
- Interest Rates: Exposure to variable interest rates on short-term debt and some long-term debt, partially managed via interest rate swaps.
- Regulatory: Operations are heavily regulated by the FDA regarding manufacturing (cGMP), clinical trials, and product approval. The Drug Enforcement Administration licenses the contract laboratory for controlled substances.
- Supply Chain: Reliance on integrated suppliers reduces the number of vendors but increases risk of interruption if a single supplier faces production problems.
Investor Verification Checklist
- Verify the full financial impact of the January 2003 Kinston, N.C. explosion, including insurance recoveries and potential litigation costs, as detailed in the "Subsequent Event" note of the Annual Report.
- Review the "Five-Year Summary" in the Annual Report to obtain specific consolidated revenue, net income, and cash flow figures not explicitly listed in this 10-K text.
- Assess the dependency on Becton Dickinson (13% of sales) and the stability of the top 10 customer base (31% of sales).
- Monitor the progress of environmental remediation at the St. Petersburg, FL facility, with expected completion in 2004.
- Evaluate the commercialization timeline for the Drug Delivery Systems segment, specifically the ChiSysTM and TargitTM technologies, which have not yet produced significant tangible income.